Derapril, but not manidipine, significantly improved baroreceptor sensitivity (from 5.0 to 5.6 msec/mm Hg) and carotid arterial distensibility (from 2.1 to 2.5 %kPa) in hypertensive patients.
RCT (n=37)
randomly allocated
Does derapril improve cardiovascular autonomic nervous system function and carotid distensibility compared to manidipine in patients with mild to moderate hypertension?
The ACE inhibitor derapril, but not the calcium channel blocker manidipine, improved autonomic balance and carotid distensibility in hypertensive patients, suggesting vascular benefits beyond blood pressure lowering.
We investigated the relationship between cardiovascular autonomic nervous system function and carotid arterial distensibility during treatment with an angiotensin converting enzyme inhibitor (derapril) or a calcium channel blocker (manidipine) for hypertension. In 37 patients with hypertension, autonomic function was assessed by heart rate variability and baroreceptor sensitivity using phenylephrine injection. Left ventricular mass index and carotid arterial distensibility were assessed by ultrasound examinations. Before the medication, both baroreceptor sensitivity and heart rate variability correlated with carotid arterial distensibility, but not with left ventricular mass index by multiple regression analysis. Subsequently, patients were randomly allocated into two groups, derapril (n = 18) and manidipine (n = 19) for 20 weeks. At the end of the study, the change in baroreceptor sensitivity correlated with change in carotid arterial distensibility (r = 0.41, P 5.6 +/- 2.0 msec/mm Hg), and carotid arterial distensibility (2.1 +/- 0.8 --> 2.5 +/- 1.0 %kPa), but the latter did not improve them at all. Thus, impairment of the autonomic balance was related to the impairment of carotid arterial distensibility in hypertension; derapril, but not manidipine, significantly improved these abnormalities.
أجرى تومياما وآخرون (الإثنين) تجربة عشوائية محكومة في حالات ارتفاع ضغط الدم الخفيف إلى المعتدل (عدد = 37). تم تقييم ديرابريل مقابل مانيديبين على حساسية مستقبلات البارورا وسعة الشرايين السباتية. حسنت ديرابريل، ولكن ليس مانيديبين، بشكل كبير حساسية مستقبلات البارورا (من 5.0 إلى 5.6 مللي ثانية/مم زئبق) وسعة الشرايين السباتية (من 2.1 إلى 2.5 %كPa) في مرضى ارتفاع ضغط الدم.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: